People living with HIV have a 1.5-to 2-fold increased risk of develo** cardiovascular
disease. Despite treatment with highly effective antiretroviral therapy, people living with HIV …

Cardiovascular disease is one of the leading causes of morbidity and mortality in people
living with HIV. Several epidemiological studies have shown an increased risk of myocardial …

Cardiovascular disease, including atherosclerosis and atherosclerosis-associated
complications, is an increasing cause of morbidity and mortality in human immunodeficiency …

Monocytes and macrophages play critical roles in HIV transmission, viral spread early in
infection, and as a reservoir of virus throughout infection. There has been a recent …

Background. Specific antiretroviral therapy (ART) medications and the severity of human
immunodeficiency virus (HIV) disease before treatment contribute to bone mineral density …

Background In the past years many inflammatory markers have been studied in association
with clinically manifest cardiovascular disease (CVD) and carotid intima-media thickness …

Objective: To determine the associations of markers of immune activation with
atherosclerosis and mortality, in participants with treated and suppressed HIV infection …

HIV-associated neurocognitive disorders (HAND) continues to be prevalent (30–50%)
despite plasma HIV-RNA suppression with combination antiretroviral therapy (cART). There …

Patients infected with the human immunodeficiency virus (HIV) have an increased
cardiovascular risk. Although initially this increased risk was attributed to metabolic …

Background Persistent inflammation and immune activation has been hypothesized to
contribute to increased prevalence of subclinical atherosclerosis and cardiovascular …